Minimizing Complications in Autoimmune Blistering Diseases

Tiffany Clay, Amit G. Pandya

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

Autoimmune blistering diseases (AIBD) often require high-dose corticosteroids and immunosuppressive agents for adequate control. These diseases cause significant morbidity but treatment can also lead to side effects and complications. This article reviews the supportive management of AIBD and the management of corticosteroid-induced side effects. The prevention and management of secondary effects from some of the more commonly used steroid-sparing agents for AIBD are summarized. Clinicians must be familiar with this information to optimally manage patients with AIBD.

Original languageEnglish (US)
Pages (from-to)577-583
Number of pages7
JournalDermatologic Clinics
Volume29
Issue number4
DOIs
StatePublished - Oct 2011

Fingerprint

Autoimmune Diseases
Adrenal Cortex Hormones
Immunosuppressive Agents
Disease Management
Secondary Prevention
Steroids
Morbidity
Therapeutics

Keywords

  • Corticosteroids
  • Emotional impact
  • Management
  • Skin lesions

ASJC Scopus subject areas

  • Dermatology

Cite this

Minimizing Complications in Autoimmune Blistering Diseases. / Clay, Tiffany; Pandya, Amit G.

In: Dermatologic Clinics, Vol. 29, No. 4, 10.2011, p. 577-583.

Research output: Contribution to journalArticle

Clay, Tiffany ; Pandya, Amit G. / Minimizing Complications in Autoimmune Blistering Diseases. In: Dermatologic Clinics. 2011 ; Vol. 29, No. 4. pp. 577-583.
@article{d93b3ec412af4c219f1afec8ff7d14b8,
title = "Minimizing Complications in Autoimmune Blistering Diseases",
abstract = "Autoimmune blistering diseases (AIBD) often require high-dose corticosteroids and immunosuppressive agents for adequate control. These diseases cause significant morbidity but treatment can also lead to side effects and complications. This article reviews the supportive management of AIBD and the management of corticosteroid-induced side effects. The prevention and management of secondary effects from some of the more commonly used steroid-sparing agents for AIBD are summarized. Clinicians must be familiar with this information to optimally manage patients with AIBD.",
keywords = "Corticosteroids, Emotional impact, Management, Skin lesions",
author = "Tiffany Clay and Pandya, {Amit G.}",
year = "2011",
month = "10",
doi = "10.1016/j.det.2011.06.005",
language = "English (US)",
volume = "29",
pages = "577--583",
journal = "Dermatologic Clinics",
issn = "0733-8635",
publisher = "W.B. Saunders Ltd",
number = "4",

}

TY - JOUR

T1 - Minimizing Complications in Autoimmune Blistering Diseases

AU - Clay, Tiffany

AU - Pandya, Amit G.

PY - 2011/10

Y1 - 2011/10

N2 - Autoimmune blistering diseases (AIBD) often require high-dose corticosteroids and immunosuppressive agents for adequate control. These diseases cause significant morbidity but treatment can also lead to side effects and complications. This article reviews the supportive management of AIBD and the management of corticosteroid-induced side effects. The prevention and management of secondary effects from some of the more commonly used steroid-sparing agents for AIBD are summarized. Clinicians must be familiar with this information to optimally manage patients with AIBD.

AB - Autoimmune blistering diseases (AIBD) often require high-dose corticosteroids and immunosuppressive agents for adequate control. These diseases cause significant morbidity but treatment can also lead to side effects and complications. This article reviews the supportive management of AIBD and the management of corticosteroid-induced side effects. The prevention and management of secondary effects from some of the more commonly used steroid-sparing agents for AIBD are summarized. Clinicians must be familiar with this information to optimally manage patients with AIBD.

KW - Corticosteroids

KW - Emotional impact

KW - Management

KW - Skin lesions

UR - http://www.scopus.com/inward/record.url?scp=80052888671&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=80052888671&partnerID=8YFLogxK

U2 - 10.1016/j.det.2011.06.005

DO - 10.1016/j.det.2011.06.005

M3 - Article

C2 - 21925001

AN - SCOPUS:80052888671

VL - 29

SP - 577

EP - 583

JO - Dermatologic Clinics

JF - Dermatologic Clinics

SN - 0733-8635

IS - 4

ER -